Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients.

Alireza AbbaspourMehdi DehghaniMahtab SetayeshMarjan TavakkoliHossein Ali RostamipourMarziyeh GhorbaniMani RamziShapour OmidvariFatemeh MoosaviOmidreza Firuzi

Published in: Cancer chemotherapy and pharmacology (2023)

These findings suggest that CDA activity could be a promising biomarker to predict survival and the occurrence of anemia in cancer patients treated with gemcitabine.

Keyphrases

papillary thyroid
locally advanced
risk assessment
chronic kidney disease
squamous cell
squamous cell carcinoma
iron deficiency
childhood cancer
young adults